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Alopecia areata, alopecia totalis, and alopecia universalis likely represent a
constellation of related diseases with similar, yet distinct heritability markers.
There is currently no known curative therapy that works universally for all
patients. Pharmacogenomic research enables the pharmaceutical industry to
understand variability of patient responses to drugs during clinical drug develop-
ment and during post-marketing surveillance. Understanding the genetic basis for
patient response/non-response can enable the development of individualized
therapies for those patients with an inherited basis for altered response to drug
therapy. There are multiple examples of drugs that now contain a recommenda-
tion for genetic testing before dosing in their drug labels, directing clinicians to
obtain genetic information for each individual patient in order to help direct drug
therapy.
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Genetic variation in individual patients
participating in clinical drug develop-
ment trials influences patient response
to therapy. The pharmaceutical industry
uses pharmacogenetic assessment of
patients participating in clinical trials
to understand if subpopulations of res-
ponders that emerge in large patient
populations are linked to genetic traits
that can be easily assessed before drug
treatment (Grecco et al., 2012; Bienfait
et al., 2013; Warner et al., 2013). By
identifying which patients will respond
to drugs before drug treatment, patients
will have reduced exposure to adverse
events and will be able to identify
effective therapies quickly without long
‘‘trial runs’’ in the clinic.
There are currently no known univer-
sally effective drug therapies for alope-
cia areata. However, there is emerging
convergence of genetic characterization
of alopecia areata patients substantiating
distinct genetic subclasses of patients—
with patients phenotypically expressing
alopecia universalis and alopecia totalis
having stronger genetic association
with disease and variation in the ULBP
(cytomegalovirus UL16-binding protein)
gene cluster on chromosome 6q25.1
(Petukhova and Duvic, 2010).
As understanding of genetic influence
for the development of disease pro-
gresses, new molecular targets for drug
therapy will be identified. By using
pharmacogenetic assessment of patients
participating in clinical drug trials for
alopecia areata, researchers will begin
to learn which patients respond more
readily to drug therapies and which
patients may be predisposed to toxicity
with particular drug therapies. Further-
more, stratification of clinical trials by
genetic subgroup rather than phenoty-
pic subtype of alopecia areata will
better characterize disease subpopula-
tions and help determine scientifically
guided approaches to drug classes that
will impact specific disease mechanism
pathways.
Because clinical trials for alopecia are
often small with limited longitudinal
follow-up, it is imperative that patient
genetic samples with broad consent for
ongoing research be collected during
clinical trials. In addition, uniform
characterization of clinical phenotype
and response across clinical trials
must be considered in order to pool
patient responses to therapy for genetic
research. This will enable genetic
studies to link to uniform clinical
response data sets in order to better
characterize genetic association with
clinical response. Patient advocacy
organizations like the National Alopecia
Areata Foundation will be critical in
bringing researchers from academia
and industry together to create large
enough research data sets to determine
best approaches for therapy.
Additionally, characterizing the life-
time disease burden for patients with
different genetic subtypes of disease
will influence overall approach to ther-
apy. For example, cosmetic treatment
of hair loss may be only a portion of the
overall treatment goal for these patients.
Systemic therapies may prove more
effective to prevent or delay additional
complications of this autoimmune
disease.
This information will translate into
individualized medical practice for
patients with alopecia areata. Research-
ers will learn how patients with alopecia
universalis and alopecia totalis respond
differentially from patients with classic
alopecia areata to available drug
therapies and create algorithm-based
approaches to drug therapy. For drugs
with known toxicities, genetic tests may
be made available to assess individual
patient risk for adverse events before
starting treatment. By assessing risk,
alternative drugs or doses of drugs can
be considered. This is especially impor-
tant for alopecia areata, which is a
chronic autoimmune disease with a
substantial portion of patients experien-
cing initial presentation in childhood.
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